Xencor, Inc. (XNCR)
NASDAQ: XNCR · Real-Time Price · USD
11.22
-0.66 (-5.56%)
At close: May 15, 2026, 4:00 PM EDT
11.00
-0.22 (-1.96%)
After-hours: May 15, 2026, 4:57 PM EDT
Xencor Revenue
Xencor had revenue of $4.52M in the quarter ending March 31, 2026, a decrease of -86.20%. This brings the company's revenue in the last twelve months to $97.36M, down -32.60% year-over-year. In the year 2025, Xencor had annual revenue of $125.58M with 13.65% growth.
Revenue (ttm)
$97.36M
Revenue Growth
-32.60%
P/S Ratio
9.05
Revenue / Employee
$374,462
Employees
260
Market Cap
831.87M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 125.58M | 15.08M | 13.65% |
| Dec 31, 2024 | 110.49M | -64.12M | -36.72% |
| Dec 31, 2023 | 174.62M | 10.04M | 6.10% |
| Dec 31, 2022 | 164.58M | -110.53M | -40.18% |
| Dec 31, 2021 | 275.11M | 152.42M | 124.23% |
| Dec 31, 2020 | 122.69M | -34.01M | -21.70% |
| Dec 31, 2019 | 156.70M | 116.10M | 285.93% |
| Dec 31, 2018 | 40.60M | -5.55M | -12.02% |
| Dec 31, 2017 | 46.15M | -62.87M | -57.67% |
| Dec 31, 2016 | 109.02M | 81.26M | 292.70% |
| Dec 31, 2015 | 27.76M | 18.24M | 191.62% |
| Dec 31, 2014 | 9.52M | -652.00K | -6.41% |
| Dec 31, 2013 | 10.17M | 648.00K | 6.80% |
| Dec 31, 2012 | 9.52M | 2.68M | 39.06% |
| Dec 31, 2011 | 6.85M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Geron | 196.12M |
| Arbutus Biopharma | 191.45M |
| Kura Oncology | 71.64M |
| Janux Therapeutics | 13.73M |
| Absci | 1.84M |
XNCR News
- 3 days ago - Xencor Transcript: Bank of America Global Healthcare Conference 2026 - Transcripts
- 4 days ago - Xencor price target raised to $14 from $13 at JPMorgan - TheFly
- 9 days ago - Xencor reports Q1 EPS ($1.71), consensus (75c) - TheFly
- 9 days ago - Xencor Reports First Quarter 2026 Financial Results - Business Wire
- 10 days ago - Xencor Transcript: Digestive Disease Week Conference - Transcripts
- 11 days ago - Xencor to host webcast to discuss XmAb942, XmAb412 data presentations - TheFly
- 11 days ago - Xencor to Host Webcast to Discuss XmAb942 and XmAb412 Data Presentations at DDW - Business Wire
- 7 weeks ago - JPMorgan downgrades Xencor on lack of ‘needle-moving’ catalysts - TheFly